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Background: To date, few studies have investigated serum vitamin D status in patients with inherited ichthyosis.
The aim of this study was to determine the prevalence of vitamin D deficiency (defined as serum level <10 ng/mL)
in a French cohort of patients and to identify associated risk factors.
Methods: This was a prospective observational study performed in a hospital reference center with expertise for
rare skin diseases. Patients’ clinical characteristics were recorded. Serum concentration of 25-hydroxyvitamin D and
parathyroid hormone were determined. For patients with vitamin D deficiency, serum calcium, serum phosphorus
and bone mineral density were also investigated. Comparisons between groups (25-hydroxyvitamin D <10 ng/mL
versus ≥10 ng/mL) were conducted by univariate and multivariate logistic regression.
Results: Of the 53 included patients, 47 (88.7%) had serum 25-hydroxyvitamin D below the optimal level of 30 ng/mL:
18 (34%) had vitamin D sufficiency, 14 (26.4%) had vitamin D insufficiency, and 15 (28.3%) had vitamin D deficiency. A
negative linear correlation was found between 25-hydroxyvitamin D and parathyroid hormone levels for the whole
study population. Serum calcium and phosphorus levels were normal for the 15 patients with vitamin D deficiency.
Bone mineral density was investigated for 11 of these latter 15 patients, and six of them had osteopenia. Winter/spring
seasons of vitamin D measurement, severity of ichthyosis, and phototypes IV–VI were identified as independent risk
factors for vitamin D deficiency.
Conclusions: Clinicians should be aware of the risk of vitamin D deficiency in the management of patients with
inherited ichthyosis, especially in winter and spring, and in case of dark skin or severe disease.
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Inherited ichthyoses are monogenic disorders of cornifica-
tion due to mutations in genes involved in skin barrier
function. Skin changes involve most of the tegument, and
are characterized by scales of various forms and severities,
and these are often associated with erythema. According
to a recent ichthyosis expert consensus, the classification
should be clinically based, and distinguishes syndromic* Correspondence: frascari.flora@gmail.com
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unless otherwise stated.from nonsyndromic ichthyoses [1]. No curative treatment
is available; however, skin condition is usually improved
by emollients, and acitretin may be used for severe cases.
Quality of life is usually affected, in particular because of
troublesome symptoms such as cutaneous pain and prur-
itus [2,3]. Ichthyoses may be complicated by episodes of
skin infection, heat intolerance, and deafness due to accu-
mulation of scales in the ear canal. Abnormally low vita-
min D (vitD) levels have also been reported as a possible
complication of the disease [4-13].
The role of vitD in bone mineralization is well docu-
mented [14], but it is also thought to have an effect onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Definitions of vitamin D status [18-24]
VitD status 25 (OH) D status (ng/ml)
Optimal x≥ 30
Sufficiency 20 ≤ x < 30
Insufficiency 10 ≤ x < 20
Deficiency x < 10
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vitD occurs when skin is exposed to UV B from sunlight,
when provitamin D is converted into previtamin D. VitD
may also be provided by food sources. Whatever its origin,
vitD requires enzymatic conversion in the liver followed
by enzymatic conversion in the kidneys to become active
[vitD is converted to 25-hydroxyvitamin D (25-(OH) D)
and then to 1,25-dihydroxyvitamin D, the active form of
vitD]. Serum 25-(OH) D level is considered to be the best
indicator of overall vitD level [17].
It is difficult to define properly normative values of
vitD because the level varies according to various fac-
tors, including sun exposure, diet, and vitD supplemen-
tation. The definitions of vitD status including optimal,
sufficiency, and insufficiency are not universally agreed
upon; however, deficiency status of vitD is commonly ac-
cepted to be 25-(OH) D <10 ng/mL [18-24].
The aim of this study was to determine the prevalence
of vitD deficiency in a French cohort of patients suffer-
ing from inherited ichthyosis, and to identify the factors
associated with this deficiency.
Methods
Study design
This study was both approved by the Ethics Committee
of Toulouse University Hospital and by the CNIL, the
French national authority for registers. It was designed
as a monocentric, prospective, observational study per-
formed in a hospital reference center with expertise for
rare skin diseases. All children (aged ≥2 years) and
adults with ichthyosis, seen in our center between
January 2011 and April 2012, were included. Data were
collected during regular follow-up.
Clinical data
A standardized questionnaire was used to record the fol-
lowing characteristics for all patients: age, sex, and form
of ichthyosis. With regard to disease severity, we evalu-
ated both erythema and scales [using visual analog scale
(VAS) 0–10], and overall severity (mild, moderate, se-
vere, or very severe). This was evaluated first by one of
the two investigators and then systematically reviewed
by the second using photography. Phototype, sun expos-
ure habits, season of vitD measurement, systemic and
topical treatment, intake of vitD supplements, and med-
ical history of fractures were also recorded.
Biological and radiological data
VitD status was defined as shown in Table 1. Serum
concentration of 25-(OH) D and parathyroid hormone
(PTH) were measured by chemiluminescent immuno-
assay. Coefficients of variation of the method
were ≤7.5% and ≤4.5% for the intra-assay variation,
and ≤13.6% and ≤6.5% for the inter-assay variation, for25-(OH) D and PTH, respectively. For patients with vitD
deficiency, we also investigated serum calcium, serum
phosphorus, and bone mineral density (BMD) [25-27].
Statistical analysis
Descriptive attributes were recorded to characterize the
population. A linear correlation (Pearson coefficient r)
was conducted between 25-(OH) D and PTH status. To
identify factors associated with vitD deficiency, compari-
sons between two groups [25-(OH) D <10 ng/mL
vs. ≥10 ng/mL] were conducted by univariate and multi-
variate logistic regression. The model included sex, age,
phototype, intensity of erythema and scales, overall se-
verity of ichthyosis, treatment with acitretin, season of
vitD measurement, and sun exposure habits. All these
potential predictors of vitD deficiency were first assessed
individually. The odds ratio (OR) significance was deter-
mined by the Wald χ2 test. Predictors with p < 0.10 were
subsequently assessed using multivariate analysis with a
backward stepwise selection procedure. Possible interac-
tions and multi-colinearity were examined. Whenever
two or more potential risk factors were highly correlated,
the predictor that was known as being more clinically
significant was selected for entry. Tests were two-sided
and p values <0.05 were considered significant. All stat-
istical analyses were performed using Medcalc version
11.5.1.
Results
Characteristics of the study population
A total of 53 patients were included and their characteris-
tics are presented in Table 2. The study population was
young (mean age <30 years, and more than one-third were
children). There was a majority of females. With regard to
the clinical form of ichthyosis, half of the patients had
autosomal recessive congenital ichthyosis (ARCI) and
~25% had common forms. Nearly one-third of the pa-
tients had dark skin (phototype IV–VI). Nearly half of the
population declared that they strictly avoided sun expos-
ure. There was no past medical history of bone fracture.
Only eight patients had been treated by acitretin or were
still receiving treatment. The pediatric population received
usual systematic supplementation with vitD; however,
adults did not receive any supplements. No other
treatment influencing vitD metabolism (including photo-
therapy) was noted.
Table 2 Patient characteristics (entire study population and patients with vitD deficiency)
Total study population (n:53) Patients with vitamin D deficiency (n:15)
Age
- Mean age (years) (±SD) 28 (±20) 25 (±13)
- Children (less than15 years and 3 months)/adults : n (%) 19 (36)/34 (64) 5 (33)/10 (67)
Gender
- Female/Male : n (%) 35 (66)/18 (34) 9 (60)/6 (40)
Form of ichthyosis
- Non syndromic ichthyosis : n (%) 47 (88.7) 13 (86.8)
- Common ichthyoses 12 (22.6) 0 (0)
- Ichthyosis vulgaris 6 (11.3) 0 (0)
- Recessive X-linked ichthyosis 6 (11.3) 0 (0)
- Autosomal recessive congenital ichthyosis 29 (54.7) 11 (73.4)
- Lamellar ichthyosis 16 (30.2) 9 (60)
- Congenital ichthyosiform erythroderma 8 (15.1) 1 (6.7)
- Bathing suit ichthyosis 4 (7.5) 1 (6.7)
- Self-healing collodion baby 1 (1.9) 0 (0)
- Keratinopathic ichthyosis (epidermolytic ichthyosis) 3 (5.7) 1 (6.7)
- Other forms 3 (5.7) 1 (6.7)
- Erythrokeratodermia variabilis 1 (1.9) 0 (0)
- Congenital reticular ichthyosiform erythroderma 1 (1.9) 1 (6.7)
- Keratosis linearis - ichthyosis congenital – keratoderma 1 (1.9) 0 (0)
- Syndromic ichthyosis : n (%) 6 (11.3) 2 (13.2)
- Netherton syndrome 3 (5.7) 0 (0)
- KID syndrome 2 (3.7) 2 (13.2)
- Neutral lipid storage disease 1 (1.9) 0 (0)
Skin features
- Erythema (VAS) mean ± SD [range] 2.20 ± 2.5 [0 – 8.5] 2.57 ± 2.5 [0 – 8.5]
- Scaling (VAS) mean ± SD) [range] 4.25 ± 2.2 [1.5 – 9] 4.80 ± 2.6 [1.5 – 9]
Overall severity
- Mild to moderate/Severe to very severe : n (%) 38 (72)/15 (28) 7 (47)/8 (53)
Phototype
- I to III/IV to VI : n (%) 39 (74)/14 (26) 8 (53)/7 (47)
Sun exposure habits
- Avoiding strictly sun exposure : n (%) 21 (45) 6 (46)
Number of patients with missing data 6 2
Season of vitamin D measurement
- Winter – spring/Summer – autumn : n (%) 30 (57)/23 (43) 13 (87)/2 (13)
Treatments
- Systemic therapy (acitretin) : n (%) 8 (15) 4 (27)
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The mean (+SD) serum level of 25-(OH) D was
18.24 ± 10 ng/mL. In 47 of the 53 patients (88.7%),
serum 25-(OH) D was below the optimal status of
30 ng/mL: 18 patients (34%) had vitD sufficiency, 14
(26.4%) had vitD insufficiency, and 15 (28.3%) hadvitD deficiency. Serum PTH was abnormally high for
10% of the patients with vitD sufficiency or insuffi-
ciency, and for 42% of the patients with vitD defi-
ciency. A negative linear correlation was statistically
found between 25-(OH) D and PTH levels (r = −0.44;
p = 0.003).
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The clinical characteristics of the 15 patients with vitD
deficiency are detailed in Table 2. There was no common
ichthyosis in this group and >70% had ARCI. Fifty-three
percent had severe or very severe disease. Nearly half had
dark skin (phototype IV–VI). Serum calcium and
phosphorus levels were normal for all 15 patients. BMD
was investigated for 11 of these 15 patients: six of them
had osteopenia, two of whom were on acitretin (Table 3).
Factors associated with vitD deficiency
Using univariate analysis (Table 4), we identified four
factors that were predictors of vitD deficiency: season of
vitD measurement (winter and spring) with an OR of
8.64 [95% confidence interval (CI): 1.59–46.81], p = 0.01;
severity of ichthyosis (severe/very severe): 8 (1.79–
35.75), p < 0.01; intensity of scales (VAS >5/10): 5.6
(1.31–24), p = 0.02; and phototype (IV–VI): 4.6 (1.11–
19.14), p = 0.04. In contrast, no statistically significant
association was found with sex, age, intensity of ery-
thema, sun exposure behavior, and acitretin therapy.
After adjustment, in multivariate analysis, only three fac-
tors were identified as independent risk factors: season
of vitD measurement [OR (95% CI): 21.87 (1.48–323.64),
p = 0.03]; severity of ichthyosis (severe/very severe) [OR
(95% CI): 14.61 (1.52–140.56), p = 0.02); and phototype
(IV–VI) [OR (95% CI): 10.94 (1.09–110.48), p = 0.04].
Discussion
This is believed to be the first study to evaluate the
prevalence of nonoptimal vitD status in a European
population with inherited ichthyoses. More than 80%
did not have an optimum status of vitD, with nearly
one-third having vitD deficiency. High grades of ichthy-
osis severity, dark skin, and winter/spring seasons were
identified as independent risk factors for vitD deficiency.Table 3 BMD measurement in patients with vitD deficiency












BMD measurements were determined using dual energy X-ray absorption scanning
BMD values are expressed as T score for adults, and Z score for children, as the num
Lines in bold reflect the patients with osteopenia.Our study had several limitations. One limitation was
the small number of patients included in the cohort
owing to the rarity of the disease (28). Another limita-
tion of the study was the inclusion of patients seen in an
expert hospital reference center for ichthyosis where the
most severe forms are seen (28% of severe or very severe
forms vs 23.5% in a recent French epidemiological study
[28]). Disease severity was identified as a risk factor;
therefore, the prevalence in the entire French ichthyosis
population (including mildest clinical forms not seen in
hospital) could be slightly lower. The absence of a con-
trol group was another limitation of the study. Neverthe-
less, the prevalence of abnormally low vitD seems to be
higher in ichthyosis than in the general healthy popula-
tion. In Boston, USA, Mitchell et al. reported that 64%
of healthy volunteers aged 18–50 years had 25 (OH)
D ≤30 ng/mL [29]. In France, Vernay et al. reported that
80.1% of healthy volunteers aged 18–74 years had 25
(OH) D <30 ng/mL and only 4.8% had 25(OH)
D <10 ng/mL [30].
Two other studies have described vitD status in ich-
thyosis. Ingen-Housz-Oro et al. reported a series of nine
adults (6 Europeans and 3 Africans) living in Paris
(France) and suffering from severe congenital ichthyosis
[31]. All had abnormally low vitD status (25 (OH)
D <30 ng/mL) and three had vitD deficiency [25 (OH)
D <10 ng/mL]. The series by Chouhan et al. studied 45
Indian children and adolescents suffering from severe or
moderate ichthyosiform erythroderma (including ichthy-
osis but also psoriasis and pityriasis rubra pilaris) [32].
In that series, 97% had 25-(OH) D <20 ng/mL compared
with 71% of the controls. This high percentage could be
explained by the presence of risk factors (all patients had
dark skin and severe disease). In the same study, PTH
level was significantly higher in the disease group than












at two standard sites: lumbar spine (L2–L4) and femoral neck (dual femur).
ber of the SD.
Table 4 Determination of the factors specifically related to vitD deficiency (univariate regression analysis procedures)
VitD deficiency
Odds ratio (CI95%) p-value
Gender (male) 1.64 [0.38 – 7.13] 0.51
Age (≥25 years) 1.6 [0.41 – 6.19] 0.5
Phototype (IV to VI) 4.6 [1.11 – 19.14] 0.04
Erythema (VAS ≥ 5/10) 0.8 [0.14 – 4.66] 0.8
Scaling (VAS≥ 5/10) 5.6 [1.31 – 24] 0.02
Ichthyosis global severity (severe-very severe) 8 [1.79 – 35.75] <0.01
Systemic therapy (acitretin) 3.25 [0.66 – 16.04] 0.15
Season (winter-spring) 8.64 [1.59 – 46.81] 0.01
Sun behavior (Sun avoidance) 1.29 [0.34 – 4.86] 0.71
Lines in bold reflect the four factors that were predictors of vitD deficiency.
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suppose that secondary hyperparathyroidism is linked to
vitD deficiency. Nevertheless, this is in contrast with the
results of the series by Milstone et al. who demonstrated
that patients suffering from ichthyosis associated with
secondary hyperparathyroidism did not have any vitD
deficiency [33].
Similarly to ichthyosis, abnormal vitD has been reported
in association with other skin diseases characterized by
abnormal scaling. Gisondi et al. recently demonstrated
that 58% of patients with psoriasis had vitD levels
<20 ng/mL compared with 30% of the control group [34].
With regard to the three identified independent risk
factors, two of these were expected: season of vitD mea-
surement and phototype. With regard to the season, the
weather is cloudy and cold in France during the winter
season, days are short, and people are usually dressed in
sweaters and long trousers. This limits the penetration of
UV B photons into the skin and therefore increases the
risk of vitD deficiency. This risk goes down in the fall and
is lowest in the summer. The spring is a good time to
measure vitD status because it gives an assessment of the
lowest level [35]. Concerning the phototype, melanin
could act as a filter and alter the synthesis of vitD in the
skin by absorbing UV photons in competition with 7-
dehydrocholesterol. It is therefore important to point out
that patients with ichthyosis are susceptible to vitD
deficiency, in part for the same reasons (season and dark
skin), as other individuals who do not have ichthyosis.
The third independent identified risk factor was dis-
ease severity. This factor is specific to the disease. The
mechanism underlying the link between vitD deficiency
and the severity of the disease remains unclear but we
can make some hypotheses. The severity of the disease
may be partly related to the severity of scales (which was
identified in univariate but not in multivariate analysis
and probably integrated in/erased by the factor ichthy-
osis severity in multivariate analysis). The presence ofscales increases the thickness of the skin and probably
reduces UV B penetration in the skin. The influence of
scales may also suggest that the intrinsic barrier defect
of ichthyosis could disturb previtamin D synthesis in the
skin. Further pathophysiological study should be per-
formed to explore this hypothesis.
One important additional point that needs to be dis-
cussed is the impact of sun avoidance on vitD level in
ichthyosis patients. In our study, no significant associ-
ation was found between sun avoidance and vitD level.
Nevertheless, it is known that because ichthyosis is a
stigmatizing condition, patients usually hide their skin
with clothes, and are therefore probably less exposed to
the sun [2]. During the summer, they also avoid the
warmth of the sun because it increases cutaneous pain
and pruritus. Therefore, their exposed skin surface area
may be less than that in the general population, reducing
the chance for UV B photons to allow vitD synthesis in
their skin. We can hypothesize that the impact of this
sun avoidance is confounded with the risk factor season.
This could be clarified in a future study restrictively per-
formed during sunny seasons, and using an appropriate
questionnaire (i.e. time spent outdoors, use of sunscreen,
and exposed skin surface area).
Based on our results, we recommend systematic
screening of 25-(OH) D in ichthyosis patients and ad-
equate supplementation if the status is not optimal [36].
Nevertheless, the real benefit of vitD status determin-
ation and supplementation was recently challenged by
Bolland et al. [37]. The author found that vitD supple-
mentation did not reduce the skeletal and nonskeletal
outcomes. However, this meta-analysis was performed in
the general population and therefore cannot be extended
to high-risk populations such as patients with ichthyosis.
Conclusions
Clinicians should be aware of the risk of vitD deficiency
in the management of patients with ichthyosis, especially
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http://www.ojrd.com/content/9/1/127in winter and spring, and in those with dark skin or
severe disease. The modalities of supplementation and
follow-up of such patients could be better defined in
further studies.
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